ロード中...
Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
OBJECTIVE: To compare drug discontinuation risk between adalimumab (ADA) and etanercept (ETN) treatment among anti-tumor necrosis factor (anti-TNF)-naïve rheumatoid arthritis (RA) patients, in particular the influence of concomitant dose of methotrexate (MTX). METHODS: This retrospective nationwide...
保存先:
| 出版年: | Patient Prefer Adherence |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751906/ https://ncbi.nlm.nih.gov/pubmed/26917952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S94396 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|